Conservative treatment of early endometrial cancer |
| |
| Authors: | Alessandro Bovicelli Giuseppina D'Andrilli Antonio Giordano Pierandrea De Iaco |
| |
| Affiliation: | 1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania;2. Department of Obstetrics and Gynecology, Unit of Oncologic Gynecology, S. Orsola‐Malpighi Hospital, University of Bologna, Bologna, Italy;3. Department of Human Pathology and Oncology, University of Siena, Siena, Italy |
| |
| Abstract: | Endometrial cancer is the most common cancer of the female genital tract in Europe and in the United States. Endometrial cancer has increased 21% in incidence since 2008, and the death rate has increased more than 100% over the past two decades. Approximately 15% of patients with endometrial cancer are pre‐menopausal. The aim of this review is to discuss the conservative management of endometrial cancer. A number of studies largely support the conservative treatment of endometrial carcinoma (EC) in women desiring future fertility. We focus on the role of progestin hormonal therapy, including the risks associated with non‐standard care, appropriate candidate selection, expected outcomes, various progestin agents and recommended follow‐up. J. Cell. Physiol. 228: 1154–1158, 2013. © 2012 Wiley Periodicals, Inc. |
| |
| Keywords: | |
|
|
